Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases

Shao, Guolianga,*; Liu, Ruibaob,*; Ding, Wenbinc; Lu, Ligongd; Li, Wentaoe; Cao, Huicunh; Liu, Rongf; Li, Caixiai; Xiang, Huak; Yang, Zhengqiangl; Yang, Jijing; Song, Jinlongj; Wang, Jianhuaf

doi: 10.1097/CAD.0000000000000690

The liver is the most common site of colorectal cancer metastases. The present study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) with raltitrexed and oxaliplatin for colorectal liver metastases in a prospective, multicenter, single-arm trial conducted in 12 hospitals from different areas in China. A total of 90 patients with colorectal liver metastases were enrolled and treated by TACE with raltitrexed 4 mg and oxaliplatin 100 mg, followed by embolotherapy with 50 mg oxaliplatin and 5–20 ml lipiodol, administered every 28 days for four cycles. Patients were followed up every 3 months after the treatment and up to 12 months. The primary endpoint was time to progression. For the full analysis set (FAS), the median time to progression and overall survival were 9.1 and 17.8 months, respectively. The disease control rate in FAS was 71 (78.9%). Grade 3 or 4 adverse events were reported for 24 (26.7%) out of all 90 patients. Grade 3 thrombocytopenia, transglutaminase abnormality, and decreased neutrophil were observed in eight (8.9%), six (6.7%), and five (5.6%) patients, respectively. No unexpected adverse events or toxic deaths were observed. TACE with raltitrexed plus oxaliplatin is feasible, clinically beneficial, and well tolerated with low-grade toxicity for colorectal cancer patients with liver metastases.

aDepartment of Radiology, Zhejiang Cancer Hospital, Hangzhou

bDepartment of Interventional Radiology, The Cancer Hospital of Harbin Medical University, Harbin

cDepartment of Interventional Radiology, The Second Affiliated Hospital of Nantong University, Nantong

dCenter of Interventional Radiology, Zhuhai Precision Medicine Center, Zhuhai People’s Hospital, Jinan University, Zhuhai

eDepartment of Interventional Therapy, Fudan University Shanghai Cancer Center

fDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University

gDepartment of Nulcear Medicine, Changhai Hospital, Second Military Medical University, Shanghai

hDepartment of Intervention, Henan Provincial People’s Hospital Affiliated to Zhengzhou University, Zhengzhou

iDepartment of Radiology, Qilu Hospital of Shandong University

jDepartment of Interventional Therapy, Shandong Tumor Hospital, Jinan

kDepartment of Interventional Radiology and Vascular Surgery, Hunan Provincial People’s Hospital, Changsha

lDepartment of Interventional Radiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China

*Guoliang Shao and Ruibao Liu contributed equally to the writing of this article.

Correspondence to Jianhua Wang, MD, PhD, Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032 China Tel: +86 136 1174 9557; fax: +86 216 403 8472; e-mail:

Received April 13, 2018

Accepted July 30, 2018

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.